Former J&J exec joins PHIOGEN as chief operations officer

PHIOGEN Pharmaceuticals, an innovative biotech start-up housed in the Texas Medical Center Innovation Hub and pioneering next-generation bacteriophage-based therapeutics, has appointed Dr Mayukh Das as chief operations officer (COO).

Dr Das joins PHIOGEN from Johnson & Johnson (NYSE: JNJ) Innovative Medicine where he served as associate scientific director of phage microbiology and brings with him more than 19 years’ experience managing medical research and pharmaceutical product development. Dr. Das, who holds a PhD in Molecular Microbiology, has also patented and successfully commercialized award-winning technology and has hands-on experience preparing regulatory submissions to the Food and Drug Administration (FDA) on behalf of biotech and large pharma.

As the COO, Dr Das will be responsible for overseeing the strategic direction and operational efficiency of the company's phage-based research and development. His deep understanding of drug discovery processes, coupled with proficiency in navigating regulatory landscapes will play a key role in advancing PHIOGEN’s therapeutic pipeline.